Home > Insider Trading > Filing (0001225208-20-007336)

Filing Details

Accession Number:: 0001225208-20-007336
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-05-08 19:17:38
Reporting Period:: 2020-05-07

Accepted Time:: 2020-05-08 19:17:38
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1099800	Edwards Lifesciences Corp	EW	Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)	364316614

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1204551	A Michael Mussallem	One Edwards Way Irvine CA 92614	Chairman & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-05-07	7,075	$0.00	44,201	No	4	A	Direct
Common Stock	Acquisiton	2020-05-08	32,850	$35.79	77,051	No	4	M	Direct
Common Stock	Disposition	2020-05-08	300	$221.58	76,751	No	4	S	Direct
Common Stock	Disposition	2020-05-08	2,900	$218.54	73,851	No	4	S	Direct
Common Stock	Disposition	2020-05-08	5,548	$217.78	68,303	No	4	S	Direct
Common Stock	Disposition	2020-05-08	6,604	$220.86	61,699	No	4	S	Direct
Common Stock	Disposition	2020-05-08	7,498	$220.10	54,201	No	4	S	Direct
Common Stock	Disposition	2020-05-08	10,000	$0.00	44,201	No	5	G	Direct
Common Stock	Acquisiton	2020-05-08	10,000	$0.00	891,194	No	5	G	Indirect	By Living Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	5	G	Direct
No	5	G	Indirect	By Living Trust

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Acquire)	Acquisiton	2020-05-07	70,700	$0.00	70,700	$218.04
Common Stock	Performance Rights	Acquisiton	2020-05-07	8,825	$0.00	8,825	$0.00
Common Stock	Employee Stock Option (Right to Acquire)	Disposition	2020-05-08	32,850	$0.00	32,850	$35.79

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
70,700	2020-06-07	2027-05-06	No	4	A	Direct
8,825	2023-05-07	2027-05-06	No	4	A	Direct
0	2013-06-14	2020-05-13	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	123,919	Indirect	401(k)

Footnotes

These restricted stock units were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019.
This transaction was executed in multiple trades at prices ranging from $221.46 to $221.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $218.24 to $219.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $217.22 to $218.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $220.43 to $221.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $219.43 to $220.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
Shares represented on the most recent statement of Issuer's 401(k) Plan Administrator.
These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.
Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.